Filed Pursuant to Rule 424(b)(3)
                                                Registration No. 333-56390


                          L.A.M. PHARMACEUTICAL, CORP.

                              Prospectus Supplement
                       (To Prospectus Dated June 7, 2001)

      Prospective investors should read this prospectus supplement and the
related prospectus carefully before investing in L.A.M.'s common stock. Both
documents contain information prospective investors should consider when making
an investment decision.

      The attached prospectus relates to the resale of shares acquired by
Hockbury Limited pursuant to an equity line of credit. Because Hockbury Limited
may sell some or all of these shares, and because there are currently no
agreements, arrangements or understandings with respect to the sale of any of
these shares, L.A.M. cannot estimate the actual number of shares that Hockbury
Limited will hold after the completion of the offering.

      The following provides information concerning the latest drawdown
requested by L.A.M.

      Date of        Date of     Shares       Average Sale      Net Proceeds
      Request         Sale        Sold       Price Per Share      to L.A.M.
      -------        -------     ------      ---------------    ------------

     04-02-02      05-03-02     416,749          $0.84         $  351,273

     The proceeds to L.A.M.  are net of the 7%  placement  agent fee paid to GKN
Securities.  GKN  Securities is the placement  agent which  introduced  Hockbury
Limited to L.A.M. and is a registered broker-dealer.

      L.A.M.'s common stock is quoted on the OTC Bulletin Board under the symbol
"LAMP". On May 3, 2002 the closing price for one share of L.A.M.'s common stock
was $1.03.

     L.A.M.  expects  to use the  proceeds  from the sale of  these  shares  for
general and  administrative  expenses,  research,  clinical trials and sales and
marketing.

              The date of this prospectus supplement is May 3, 2002.